SK Bioscience Applies for Phase 3 Clinical Trial Plan of COVID-19 Vaccine in Nepal

[Asia Economy Reporter Minji Lee] SK Bioscience announced on the 8th that it has applied for a Phase 3 clinical trial plan for the heterologous booster shot of the COVID-19 vaccine GBP510 in Nepal.

The company stated, “GBP510 is a SARS-CoV-2 recombinant protein nanoparticle vaccine using the adjuvant AS03. It is expected to enhance the immune response, which decreases over time after the primary vaccination, through a heterologous booster shot, while also ensuring sufficient safety.”